Research
Hormonal
Dual GIP/GLP-1 agonists are more effective in treating obesity than GLP-1 agonists alone.
Consider dual GIP/GLP-1 agonists for potentially better outcomes in obesity treatment.
StrongSupportsmedium confidence
It is also found that dual gastric inhibitory polypeptide (GIP)/GLP-1 agonists is regarded as the more effective in treating obesity than the GLP-1 agonist alone.
Why this rating
Based on published clinical data from various clinical trials.
Source
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Nidhi Sharma et al. · Journal of Diabetology · 2023
DOI 10.4103/jod.jod_102_22
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →